COSA 2020: Next-Generation Sequencing Proves Feasible in Rare Cancers and Identifies Potentially Actionable Results
Genomic biomarkers leading to potential treatment have been spotted in half of cases.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.